Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. [electronic resource]
Producer: 20200413ISSN:- 1422-0067
- Animals
- Diabetes Mellitus, Type 2 -- drug therapy
- Diabetic Nephropathies -- drug therapy
- Drug Synergism
- Glucagon-Like Peptide-1 Receptor -- metabolism
- Humans
- Hypoglycemic Agents -- pharmacology
- Kidney -- drug effects
- Sodium-Glucose Transporter 2 -- metabolism
- Sodium-Glucose Transporter 2 Inhibitors -- pharmacology
- Glucagon-Like Peptide-1 Receptor Agonists
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.